This article was originally published in The Gray Sheet
Series A private placement will provide a total of $7 mil. in funding, contingent upon certain milestones. The privately held San Diego developer of high-throughput target validation systems and single nucleotide polymorphism (SNP)-based diagnostics notes that the funds "will enable the company to expand its platform technology to address substantially larger numbers of candidate genes in much shorter time frames"
You may also be interested in...
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.